IL162726A0 - Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections - Google Patents

Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections

Info

Publication number
IL162726A0
IL162726A0 IL16272603A IL16272603A IL162726A0 IL 162726 A0 IL162726 A0 IL 162726A0 IL 16272603 A IL16272603 A IL 16272603A IL 16272603 A IL16272603 A IL 16272603A IL 162726 A0 IL162726 A0 IL 162726A0
Authority
IL
Israel
Prior art keywords
cox
inhibitors
treatment
combination
antiviral agents
Prior art date
Application number
IL16272603A
Other languages
English (en)
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of IL162726A0 publication Critical patent/IL162726A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82BNANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01LSEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/027Making masks on semiconductor bodies for further photolithographic processing not provided for in group H01L21/18 or H01L21/34

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Power Engineering (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16272603A 2002-01-10 2003-01-10 Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections IL162726A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34755002P 2002-01-10 2002-01-10
PCT/US2003/000016 WO2003059347A1 (en) 2002-01-10 2003-01-10 Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections

Publications (1)

Publication Number Publication Date
IL162726A0 true IL162726A0 (en) 2005-11-20

Family

ID=23364195

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16272603A IL162726A0 (en) 2002-01-10 2003-01-10 Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections

Country Status (16)

Country Link
US (1) US20030211163A1 (pt)
EP (1) EP1463500A1 (pt)
JP (1) JP2005519061A (pt)
KR (1) KR20040072720A (pt)
CN (1) CN1697654A (pt)
AU (1) AU2003201811A1 (pt)
BR (1) BR0306820A (pt)
CA (1) CA2472459A1 (pt)
CO (1) CO5590913A2 (pt)
IL (1) IL162726A0 (pt)
MX (1) MXPA04006572A (pt)
NO (1) NO20043313L (pt)
PL (1) PL371252A1 (pt)
RU (1) RU2004121147A (pt)
WO (1) WO2003059347A1 (pt)
ZA (1) ZA200404881B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
EP2267010B1 (en) 1999-08-25 2014-05-07 Allergan, Inc. Activatable recombinant neurotoxins
AU2003243215A1 (en) * 2002-05-30 2003-12-19 Pharmacia And Upjohn Company Treatment for human papillomavirus
EP1572186A2 (en) * 2002-12-19 2005-09-14 Pharmacia Corporation Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
US8940755B2 (en) 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US20060229347A1 (en) * 2005-03-30 2006-10-12 Astion Development A/S Treatment of eczemas
US8609623B2 (en) * 2005-05-18 2013-12-17 Alt Solutions Inc. Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
KR100644968B1 (ko) * 2005-10-28 2006-11-14 한국과학기술연구원 생체적합성 실리콘 나노입자의 제조 방법
US20080119820A1 (en) 2006-09-20 2008-05-22 Phan Phillip C Methods for Delivering Volatile Anesthetics for Regional Anesthesia and/or Pain Relief
ITRM20080027A1 (it) * 2008-01-18 2009-07-19 Maria Balestrieri Uso di aciclovir per il trattamento delle condilomatosi.
EP2244737B1 (en) 2008-01-22 2019-04-10 The Board of Regents of The University of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US20090258843A1 (en) * 2008-04-15 2009-10-15 Mallinckrodt Inc. Compositions Containing Antiviral Compounds and Methods of Using the Same
IL192335A0 (en) * 2008-06-19 2011-08-01 Avivi Easy Life Ltd Antiviral compounds
US20110218241A1 (en) * 2010-03-06 2011-09-08 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
JP2012020991A (ja) * 2010-06-16 2012-02-02 Takasago Internatl Corp 経皮吸収促進剤、及びこれを含有する皮膚外用製剤
US9173863B2 (en) 2012-02-06 2015-11-03 Innovative Med Concepts, LLC Antiviral compound and COX-2 inhibitor combination therapy for functional somatic syndromes, including combination of famciclovir and celecoxib
TWI646091B (zh) * 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
WO2016036588A1 (en) * 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Pharmaceutical suspensions containing etoricoxib
CN105906496A (zh) * 2016-05-16 2016-08-31 苏州毕诺佳医药技术有限公司 一种阿昔洛韦的药物组合物及其医药用途
CN117860740A (zh) * 2020-12-28 2024-04-12 中以海德人工智能药物研发股份有限公司 一种用于治疗或预防病毒性肝炎的药物组合物及其应用
EP4340884A1 (en) * 2021-05-19 2024-03-27 University of Miami Treatment of infections in and around the eye

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
EP1288206B1 (en) * 1996-04-12 2008-09-17 G.D. Searle LLC Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CA2313049A1 (en) * 1997-12-17 1999-06-24 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
CN1353573A (zh) * 1999-05-14 2002-06-12 加利福尼亚大学董事会 对炎症介导感染的抗炎症治疗
US20030004142A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
US20030004143A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the female reproductive tract

Also Published As

Publication number Publication date
US20030211163A1 (en) 2003-11-13
JP2005519061A (ja) 2005-06-30
KR20040072720A (ko) 2004-08-18
BR0306820A (pt) 2004-12-07
NO20043313L (no) 2004-10-08
PL371252A1 (en) 2005-06-13
AU2003201811A1 (en) 2003-07-30
WO2003059347A1 (en) 2003-07-24
RU2004121147A (ru) 2005-04-10
CA2472459A1 (en) 2003-07-24
EP1463500A1 (en) 2004-10-06
ZA200404881B (en) 2005-08-31
MXPA04006572A (es) 2005-11-04
CO5590913A2 (es) 2005-12-30
CN1697654A (zh) 2005-11-16

Similar Documents

Publication Publication Date Title
IL162726A0 (en) Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections
NL301115I2 (nl) Drospirenon in combinatie met estetrol
EE200500011A (et) Indasoolid, bensotiasoolid ja bensoisotiasoolid, nende valmistamine ning kasutamine
HK1097256A1 (en) Pyrizdazine derivatives and their use as therapeutic agents
IL158985A0 (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
SI1757606T1 (sl) Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
EP1549614A4 (en) VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
AU2003213768A8 (en) Use of benzimidazole analogs in the treatment of cell proliferation
PL376454A1 (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections
HK1092016A1 (en) Antiviral agent and fibers and antiviral members using the same
EP1543034A4 (en) TREATMENT AND PROPHYLAXIS WITH 4-1BB BINDING AGENTS
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
IL173188A0 (en) Use of alcohol-oxyalkyates in the form of adjuvants for benzamidoxime gungicidal derivatives, appropriate agents and kits
AU2003231947A8 (en) Defensins: use as antiviral agents
GB2411354B (en) Use of Scutellaria for the treatment of viral infections
DE60220060D1 (de) Wirbelbildung inhibitor mit opferkörper
PL377427A1 (pl) Sposoby i kompozycje do leczenia infekcji wirusem opryszczki z zastosowaniem inhibitorów selektywnych względem cyklooksygenazy-2 lub inhibitorów cyklooksygenazy-2 w połączeniu ze środkami przeciwwirusowymi
IL159879A0 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
GB0415181D0 (en) Compounds for use in the treatment of infection
NL1027109A1 (nl) Verbinding en gebruik bij behandeling.
GB0300078D0 (en) Composition for the treatment of HIV and AIDS